Exploring therapeutic mechanisms of San-Huang-Tang in nonalcoholic fatty liver disease through network pharmacology and experimental validation
Author:
Funder
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Drug Discovery,Pharmacology
Reference46 articles.
1. FoxO1 signaling as a therapeutic target for type 2 diabetes and obesity;Benchoula;Eur. J. Pharmacol.,2021
2. Racial differences in prevalence and severity of non-alcoholic fatty liver disease;Bonacini;World J. Hepatol.,2021
3. Analysis of the correlation between dampness syndrome of traditional Chinese medicine and the degree of nonalcoholic fatty liver;Cheng;Western Traditional Chinese Medicine,2020
4. Traditional Chinese herbs as chemical resource library for drug discovery of anti-infective and anti-inflammatory;Ding;J. Ethnopharmacol.,2014
5. San-Huang-Tang protects obesity/diabetes induced NAFLD by upregulating PGC-1α/PEPCK signaling in obese and galr1 knockout mice models;Fang;J. Ethnopharmacol.,2020
Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Chinese medicine in the treatment of non-alcoholic fatty liver disease based on network pharmacology: a review;Frontiers in Pharmacology;2024-04-17
2. Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies;Chinese Medicine;2024-02-03
3. Analysis of network pharmacology and experimental verification to explore the mechanism of Modified Guilu Erxian Glue in the treatment of low immune function;Pharmacological Research - Modern Chinese Medicine;2023-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3